Buzz: A buyer is in talks to acquire a big stake in Celltrion

The buzz about the potential sale of a big stake in Celltrion, Korea's biosimilars developer, picked up after the company filed a statement with regulators indicating that discussions with a potential buyer or buyers are underway. Celltrion recently won an approval in Europe for its copycat version of Remicade. The company president retained JP Morgan last year to help market his stake in the company. Story

Suggested Articles

It’s been a good year for Intellia: One of its founders, Jennifer Doudna, Ph.D., nabbed the Nobel Prize in Chemistry for her CRISPR research.

After stints at Eli Lilly, Boehringer Ingelheim and Bristol Myers Squibb, Sid Kerkar, M.D., is hopping over to a small biotech.

Two long noncoding RNAs called TROLL-2 and TROLL-3 influence protein signaling to drive the progression of breast cancer, a new study revealed.